Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art.
Rimini M, Presi S, Pipitone GB, Russo Raucci A, Ratti F, Della Corte A, Pedica F, Vanella G, Tonon G, Burgio V, Vitiello F, Rossari F, Amadeo E, Maria Giulia C, Pecciarini L, Arcidiacono PG, Falcinelli F, Cascinu S, De Cobelli F, Aldrighetti L, Patricelli MG, Carrera P, Casadei-Gardini A. Rimini M, et al. Among authors: burgio v. Expert Rev Gastroenterol Hepatol. 2024 Apr-May;18(4-5):141-146. doi: 10.1080/17474124.2024.2337000. Epub 2024 Apr 8. Expert Rev Gastroenterol Hepatol. 2024. PMID: 38584510
Cholangiocarcinoma: new perspectives for new horizons.
Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: burgio v. Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1367-1383. doi: 10.1080/17474124.2021.1991313. Epub 2021 Nov 9. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34669536 Review.
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, Nichetti F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, De Braud F, Puzzoni M, Frassineti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: burgio v. Eur J Cancer. 2022 Aug;171:232-241. doi: 10.1016/j.ejca.2022.05.004. Epub 2022 Jun 21. Eur J Cancer. 2022. PMID: 35749808
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.
Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, Kudo M, Kawaguchi T, Hatanaka T, Nouso K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: burgio v. Hepatol Res. 2022 Dec;52(12):1050-1059. doi: 10.1111/hepr.13824. Epub 2022 Aug 25. Hepatol Res. 2022. PMID: 35960789
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Lavacchi D, Personeni N, Ratti F, Pedica F, Della Corte A, Persano M, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: burgio v. Target Oncol. 2022 Sep;17(5):591-596. doi: 10.1007/s11523-022-00917-7. Epub 2022 Sep 17. Target Oncol. 2022. PMID: 36114954
118 results